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Summary:Targeted pre-emptive fluconazole initiated at 800 mg/day following post-
screening lumbar puncture to exclude underlying cryptococcal meningitis in blood 
cryptococcal antigen (CrAg)-positive asymptomatic patients starting antiretrovirals at less 
than 100 CD4 cells/μL, significantly reduces incidence of CM and has some survival benefits.   
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Abstract 
Cryptococcal antigen (CrAg) screening and targeted pre-emptive fluconazole in antiretroviral 
naive HIV-infected adults with less than 100 CD4 cells/μL seems promising to reduce the 
burden of cryptococcal meningitis (CM). We searched MEDLINE, EMBASE, and Web of 
Science and used random-effect meta-analysis to assess the prevalence of blood CrAg-
positivity (31 studies; 35,644 participants) and asymptomatic CM in CrAg-positives, 
incidence of CM and all-cause mortality in screened participants. Pooled prevalence of blood 
CrAg-positivity was 6% (95%CI: 5 – 7) and asymptomatic CM in CrAg-positives was 33% 
(95%CI: 21 – 45). Incidence of CM without pre-emptive fluconazole was 21.4% (95%CI: 
11.6 – 34.4) and 5.7% (95%CI: 3.0 – 9.7) with pre-emptive fluconazole initiated at 800 
mg/day. In CrAg-positives, post-screening lumbar puncture prior to initiating pre-emptive 
fluconazole at 800 mg/day further reduced incidence of CM to null and showed some 
survival benefits. However, all-cause mortality remained significantly higher in CrAg-
positives than CrAg-negatives: RR: 2.2 (95%CI: 1.7 – 2.9, p<0.001).  
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INTRODUCTION  
Cryptococcal meningitis (CM) is due to a ubiquitous environmental encapsulated yeast, 
Cryptococcus spp, and occurs primarily in patients with advanced defective cell-mediated 
immunity [1, 2]. Consequent to the HIV pandemic, there has been a remarkable surge in the 
incidence of CM, especially in Sub-Saharan Africa [3, 4]. In such settings, over 90% of CM 
occur in HIV-infected patients [5, 6]. With the introduction of antiretroviral therapy (ART) in 
the 1990s, the incidence of CM has declined in high-income countries (HIC) [7, 8]. However, 
in low- and middle-income countries (LMIC), around 20% of patients still present to HIV 
care with less than 100 CD4 cells/μL, a major risk factor for developing CM [4, 9]. In LMIC 
settings, CM accounts for around 15% of HIV-related mortality [4] with in-hospital case 
fatality rates ranging between 30 – 60% in recent Sub-Saharan African cohorts [6, 10-13]. 
There is therefore urgent need for effective preventive strategies to reduce the burden of CM 
[14]. The “blanket” strategy no longer recommended, relied on fluconazole-based primary 
prophylaxis in all patients with less than 100 CD4 cells/μL [15]. Though this strategy was 
shown to reduce the incidence of CM [16], it was not widely implemented because of lack of 
evidence on survival benefits, potential for inducing resistance to fluconazole and high cost. 
This prompted experts to suggest targeted pre-emptive fluconazole therapy to patients 
identified at higher risk of CM who are more likely to benefit from this pre-emptive treatment 
[17].  
Cryptococcus contains a capsular polysaccharide, known as cryptococcal antigen (CrAg), 
which can be detected in blood weeks to months prior to onset of CM [18]. Evidence 
suggests that without fluconazole therapy, CrAg-positive patients have up to 25% risk of CM 
in the first year of ART [14, 19]. Thus, in 2011, the World Health Organisation (WHO) 
suggested routine CrAg screening in ART-naïve HIV-infected adults with less than 100 CD4 
cells/μL, using either latex agglutination (LA) or lateral flow assay (LFA) procedures [20] 
(LFA easier and results obtained within ten minutes [21]). Following WHO’s advice, CrAg-
positive patients without meningitis should be offered pre-emptive oral fluconazole at a 
tapering dose of 800 mg/day for two weeks, then 400 mg/day for eight weeks, followed by 
200 mg/day until control CD4 is above 200 cells/μL [20]. Nonetheless, this recommended 
dosage remains provisional because the optimal antifungal regimen for this population is not 
clearly established [22].  
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CrAg screening with targeted pre-emptive fluconazole therapy seems attractive and cost-
effective [23-26], but how best to implement it in overstretched, under-resourced high disease 
burdened health care settings remains a challenge. Nevertheless, it is incorporated into 
several national HIV care guidelines, both in LMIC (Botswana, Kenya, Mozambique, 
Namibia, Rwanda, South Africa, Swaziland, Uganda) and HIC settings (USA and France) [4, 
27]. Though promising, a systematic assessment of the impact of this strategy is lacking. We 
therefore performed a systematic review and meta-analysis (SRMA) to assess four key 
clinical outcomes of routine CrAg screening and targeted pre-emptive fluconazole therapy in 
ART-naïve HIV-infected adults with less than 100 CD4 cells/μL: the prevalence of CrAg 
positivity, the prevalence of asymptomatic CM in CrAg-positives, the incidence of CM and 
all-cause mortality during follow-up in screened participants. 
METHODS 
Search strategy and study selection  
A medical information specialist (RS) developed a comprehensive search strategy to identify 
published and unpublished studies in MEDLINE, EMBASE, and Web of Science. Medical 
subject headings (MeSH) and keywords included: “cryptococcal antigen”, “cryptococcal 
surface polysaccharides”, “cryptococcal meningitis”, “HIV”, “screening”, “detection”, “latex 
agglutination”, “lateral flow assay” (Supplementary Table 1). To avoid missing relevant 
studies, we did not use methodological filters. Searches were run from January 1981 (year of 
first HIV case) through April 2018. References of included studies and previous reviews on 
the subject were screened for eligibility. Reports that cited included studies were also 
searched on Google Scholar. Conference proceedings of the Conference on Retroviruses and 
Opportunistic Infections (CROI), the International Conference on Cryptococcus and 
Cryptococcosis (ICCC), and the International AIDS Society (IAS) conference were screened 
from 2010 onwards. 
Two review authors (ET, JJB) independently screened studies by title and abstract and 
assessed full texts of potentially relevant studies. Discrepancies were discussed and when 
consensus was not reached, study inclusion was further discussed with a third author (JFC). 
Study selection was done using Rayyan systematic reviews online application 
(http://rayyan.qcri.org).  
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We included cross-sectional studies, randomised controlled trials (RCT), and cohort studies 
(retrospective and prospective) in which study participants were screened for CrAg using LA 
or LFA procedures. Case-control studies and case reports were excluded. Study participants 
had to be HIV-infected adults (age >18 years) presenting to HIV-care programs with less than 
100 CD4 cells/μL, naïve to ART, with no symptoms suggestive of CM, in whom serum CrAg 
screening was done prior to ART initiation. There was no country restriction. Only studies 
published in English, French and Spanish were included.  
In this review, the main intervention of interest was pre-emptive fluconazole therapy in 
CrAg-positive patients. However, to the best of our knowledge, there is no RCT evaluating 
the effectiveness of this intervention. A placebo-controlled trial would be unethical because 
there is enough clinical evidence to suggest that fluconazole therapy may reduce the risk of 
CM in severely immunosuppressed HIV-infected patients [16]. Consequently, in the present 
review, the impact of this intervention was evaluated based on observational studies. 
Our clinical outcomes of interest were: (i) the prevalence of blood (serum/plasma) CrAg 
positivity in screened participants, (ii) the prevalence of asymptomatic CM (ascertained by 
positive fungal culture and/or Indian ink staining and/or CrAg in cerebrospinal fluid [CSF]) 
in blood CrAg-positive patients, (iii) the incidence of CM during follow-up, and (iv) all-cause 
mortality during follow-up.  
Data extraction and quality assessment  
For each study, we extracted: 
 Study characteristics: first author, publication year, design (RCT, cohort, cross-
sectional), country; 
 Participant characteristics: total number, proportion of ART-naïve, number with less 
than 100 CD4 cells/μL; 
 CrAg screening test procedure: LA or LFA;  
 CrAg screening outcome: number screened, number and proportion of CrAg-positive  
 Interventions offered to CrAg-positive patients: lumbar puncture (number of confirmed 
asymptomatic CM), pre-emptive fluconazole therapy (offered or not, number of 
participants offered fluconazole, initial dose offered, duration), ART (median time to 
initiation if available); 
 Clinical outcomes within follow-up: incidence of CM (number and proportion in CrAg-
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positive and CrAg-negatives), all-cause mortality (number and proportion in CrAg-
positive and CrAg-negatives), number lost to follow-up within each group, if reported;  
We assessed risk of bias only in studies where screened patients were subsequently followed 
up. For this, we adapted a quality assessment tool (Supplementary Table 2) based on the 
Joanna Briggs Institute checklist for cohort studies [28]. The main components of the review 
question considered were: study population (HIV-infected adults with less than 100 CD4 
cells/μL), exposure (CrAg status and the method used to determine it), intervention (targeted 
pre-emptive fluconazole therapy or not, ART to screened patients), and the outcomes of 
interest during follow-up (incidence of CM and all-cause mortality). For each study, we 
assessed patient selection bias, treatment allocation bias, outcome assessment bias and 
completeness of outcome data bias. Where insufficient information was reported we 
contacted study authors for clarification. 
Data analysis  
Data were pooled using standard random-effects meta-analysis for proportions using the 
Freeman-Tukey double arcsine transformation and the metaprop command [29] in STATA 
15.0 (Statacorp, Texas, USA) to estimate the prevalence of CrAg positivity in screened 
participants and the prevalence of asymptomatic CM in CrAg-positive participants, and 
reported with their 95% confidence interval (95%CI).  
In studies where screened participants were subsequently followed up, random-effects 
models were used in Review manager (Revman) version 5.3 [30] to estimate the incidence of 
CM and all-cause mortality during follow-up as well as risk ratios (RR) comparing CrAg-
positive to CrAg-negative participants. This analysis was stratified by the type of 
interventions offered to CrAg-positive participants (i.e., no pre-emptive fluconazole, pre-
emptive fluconazole initiated at <800 mg/day or 800 mg/day or initiated at 800 mg/day 
following post-screening lumbar puncture).  
Heterogeneity was evaluated graphically by observing forest plots and by calculating I² 
statistics. Additional stratified analysis was performed to explore heterogeneity when I² was 
greater than 50%.  
The protocol was registered in the PROSPERO international prospective register of 
systematic reviews, registration number CRD42018087608. 
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The electronic search ran on April 20
th
, 2018 identified 2,115 citations (314 duplicates). 
Based on title and abstract screening, 1,741 citations were excluded (Figure 1). On further 
assessment of 60 citations, 29 more were excluded. A total of 31 studies were included for 
estimating the prevalence of CrAg positivity [14, 22, 23, 26, 31-57], of which ten to evaluate 
the prevalence of asymptomatic CM in CrAg-positive participants [31, 33, 40, 41, 45, 48, 50, 
51, 55, 57], four to evaluate the incidence of CM and all-cause mortality in the context of no 
fluconazole pre-emptive therapy [14, 32, 35, 49], and twenty to evaluate the incidence of CM 
and/or all-cause mortality in the context of pre-emptive fluconazole therapy [14, 22, 23, 32, 
33, 35, 39-45, 48-51, 53, 55, 56]. The quality of included studies is summarised in 
Supplementary text and Supplementary Figure 1. 
Prevalence of blood CrAg positivity and asymptomatic CM in CrAg-positives 
Thirty-one studies from 22 countries (67.7% Sub-Saharan African) were included [14, 22, 23, 
26, 31-57] of which 22 (71%) cohorts, 3 (9.7%) randomised trials, and 6 (19.4%) cross-
sectional (Table 1). In these, 38,383 participants underwent CrAg screening irrespective of 
CD4 count, of whom 35,644 (92.9%) had less than 100 CD4 cells/μL (our target population). 
Screening was done with LFA in 20 (64.5%) studies, and LA in the rest. Screening was 
performed in real-time on fresh sera in 20 (64.5%) studies and retrospectively on stored sera 
in 11 (35.5%). In participants with >100 CD4 cells/μL, the median prevalence of CrAg 
positivity was 2% (Interquartile range [IQR]: 1 – 3). In those with <100 CD4 cells/μL, CrAg 
positivity ranged from 0 - 21% and pooled prevalence was 6% (95%CI: 5 – 7; I2 = 89.3%) 
(Figure 2). Pooled CrAg prevalence was slightly higher with LA than LFA: 8% (95%CI: 5 -
11; I
2 
= 90.34%) vs 5% (95%CI: 4 – 6, I2 = 88.9%), p = 0.13, respectively; in prospective 
than retrospective cohorts: 6% (95%CI: 5 – 8, I2 = 83.8%) vs 5% (95%CI: 3 – 8, I2 = 87.6%), 
p = 0.78 and in fresh than stored sera: 7% (95%CI: 5 – 9, I2 = 89.9%) vs 6% (95%CI: 5 – 7, I2 
= 76.4%), p = 0.02, respectively (Supplementary Figures 2 and 3).  
Following CrAg screening, lumbar puncture (LP) was offered to CrAg-positive participants 
(who presented no symptoms of CM) in 10 studies [31, 33, 40, 41, 45, 48, 50, 51, 55, 57]. 
Among the 403 participants eligible for LP, 276 (68.5%) accepted and the pooled prevalence 
of confirmed asymptomatic CM in CrAg-positives was 33% (95%CI: 21 – 45; I2 = 76.1%); 
Figure 3. 
RESULTS  
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During the median follow up of 1-year (IQR: 0.5 – 1), when CrAg-positive participants were 
not offered pre-emptive fluconazole, incidence of CM was 21.4% (95%CI: 11.6 – 34.4) vs 
0.4% (95%CI: 0.1 – 1) in CrAg-negatives (Table 2, Figure 4.1).  
When pre-emptive fluconazole was offered to CrAg-positives, stratifying by initial dose, less 
than 800 mg/day was associated with more incident cases of CM than 800 mg/day: 9.1% 
(95%CI: 2.5 – 21.7) vs 5.7% (95%CI: 3.0 – 9.7), Figure 4.2. In these analyses, incidence was 
consistently less than 1% in CrAg-negatives (Table 2). Moreover, performing LP to CrAg-
positive participants to exclude those with confirmed asymptomatic CM prior to initiating 
pre-emptive fluconazole at 800 mg/day significantly reduced the incidence of CM to similar 
levels in CrAg-negatives: 0% (95%CI: 0 – 0.8) and 0.4% (95%CI: 0 – 1), p = 0.12, 
respectively and this was independent of CrAg test used (Supplementary figure 4.1). 
Incidence of all-cause mortality 
Following CrAg screening, when no pre-emptive fluconazole was offered to CrAg-positives, 
incidence of all-cause mortality during follow-up was significantly higher than in CrAg-
negatives: 39.7% (95%CI: 28.8 – 51.5) vs 13.9% (95%CI: 11.8 – 16.2), respectively (Table 3, 
Figure 5.1). Offering pre-emptive fluconazole at 800 mg/day was associated with decreased 
mortality risk in CrAg-positives compared to no fluconazole: 17.4% (95%CI: 13.9 – 21.4). 
Nevertheless, incidence of all-cause mortality remained significantly higher in CrAg-
positives than in CrAg-negatives even after excluding CrAg-positives with asymptomatic CM 
prior to initiating fluconazole at 800 mg/day, RR: 2.2 (95%CI: 1.7 – 2.9, p<0.001) (Table 3, 
Figure 5.3), independent of CrAg test used (Supplementary figure 4.2)  
DISCUSSION 
Main findings  
This SRMA shows that (i) the prevalence of CrAg positivity in asymptomatic HIV-infected 
patients with less than 100 CD4 cells/μL is around 6% [4, 58], (ii) among CrAg-positives, the 
prevalence of asymptomatic CM is approximately 30%, (iii) the incidence of CM in CrAg-
positives drops from around 20% without pre-emptive fluconazole to 5% with pre-emptive 
fluconazole initiated at 800 mg/day, (iv) initiating pre-emptive fluconazole at 800 mg/day 
after excluding asymptomatic CM reduced overall mortality in CrAg-positives from around 
40% to around 20%, but CrAg-positives still had more than two-fold risk of death than CrAg-
negatives. 
Incidence of cryptococcal meningitis 
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Implications for practice  
Our findings show that targeted pre-emptive fluconazole initiated at 800 mg/day may reduce 
the incidence of CM from around 20% to around 5%, thus strong evidence of its 
effectiveness. Furthermore, when CrAg-positive patients were offered post-screening lumbar 
puncture, the incidence of CM even reduced further to less than 1%, which is comparable to 
that observed in CrAg-negatives. This supports systematically offering LP to CrAg-positives 
to prevent clinically asymptomatic patients with CSF evidence of meningitis from receiving 
sub-optimal induction antifungal treatment with fluconazole monotherapy, known to be less 
effective in CM even at highest dosages [59, 60]. In other words, the observed incident CM 
cases during follow-up despite pre-emptive fluconazole therapy might be a resultant of 
insufficient treatment and unmasking secondary to immune reconstitution inflammatory 
syndrome [61]. We therefore suggest that the objective is not only to identify CrAg-positive 
patients, but also, among them, those who have asymptomatic CM. Patients with 
asymptomatic CM should be treated with recommended induction antifungal combination 
therapy: one-week Amphotericin B plus flucytosine or oral high dose fluconazole plus 
flucytosine [62], while fluconazole pre-emptive therapy should be restricted to those without 
CSF evidence of CM. 
In studies reporting the experience of routine CrAg screening and targeted fluconazole 
therapy in LMIC settings, we found little heterogeneity, suggesting similarities across these 
studies in the overall implementation of the CrAg screen-and-treat strategy: tests used, 
classification of patients as CrAg-positives or -negatives, fluconazole to CrAg-positive 
patients, post-screening ART initiation, follow-up and reporting of ascertained CM cases 
over time. However, there was much variability in the way fluconazole was offered to CrAg-
positive patients in terms of dosage and duration. Few studies provided fluconazole at the 
WHO-suggested tapering dose and duration [40, 42, 43, 45, 48, 51-53, 55]. In some, 
fluconazole was initiated at 800 mg/day and provided for four weeks only [41] or for two 
weeks then 400 mg/day for another two weeks and stopped [22]; these short courses seemed 
to be due to local realities of insufficient fluconazole availability. This shows that for targeted 
pre-emptive therapy to be effective as a preventive strategy for CM, readily available and 
sustainable fluconazole is a prerequisite, especially as CrAg point-of-care tests are becoming 
more available [21, 63] and accepted by clinicians and patients.  
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Given that most studies show moderate lumbar puncture feasibility and acceptance (68.5%), 
there is critical need for more acceptable methods for identifying those with asymptomatic 
CM among CrAg-positives. With existing evidence of association between serum CrAg titres 
and asymptomatic CM [43, 45, 55, 57, 64], systematic per-screening CrAg quantification can 
be done, and a threshold defined beyond which patients could be considered for 
recommended inductive combination antifungal therapy [62]. Available evidence suggests 
such a threshold is around 1:160 [45, 55, 57, 64] and a recent Ugandan study [43] showed 
strong association between this titre level and incident CM within weeks of ART initiation. 
Future research should aim at evaluating whether semi-quantitative point-of-care CrAg tests 
[55, 63] capable of identifying patients with high titres [65] would increase the effectiveness 
of pre-emptive therapy. 
With regards to the effect of targeted pre-emptive therapy on all-cause mortality, we found 
some evidence that initiating fluconazole at 800 mg/day in CrAg-positive patients exempt of 
asymptomatic CM may have some benefits on mortality during the first year of ART 
initiation. However, mortality was still significantly higher than in CrAg-negative patients 
suggesting the existence of poorly understood non-CM CrAg status-related mortality 
predispositions worthy of further exploration. Perhaps, following ART initiation, CrAg 
positivity may affect immune response to other opportunistic infections leading to death. 
Further research could therefore focus on quality of immune responses following ART 
initiation, comparing CrAg-positives to CrAg-negatives.  
Study limitations  
Our study has some limitations. The effect of pre-emptive fluconazole on the incidence of 
CM and all-cause mortality in CrAg-positive patients was indirectly evaluated because most 
of the included studies were observational with very few RCTs. Even the included RCTs, 
none was randomised to compare pre-emptive fluconazole to no fluconazole or to an 
alternative pre-emptive therapy in CrAg-positive patients. Consequently, we report only 
indirect evidence for the effectiveness of the WHO CrAg screen-and-treat strategy. 
Furthermore, not all studies evaluated our predefined main outcomes of interest and this 
resulted in variable denominators (number of studies and number of participants) across the 
outcomes. Also, the data were scarce for several outcomes, with zero cells leading to unstable 
estimates and wide confidence intervals. We acknowledge that effects on incidental CM 
cases and mortality rates during follow-up would have been better assessed through more 
Implications for research  
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy567/5055339
by London School of Hygiene & Tropical Medicine user
on 20 July 2018
 11 
 
reliable survival methods that account for censoring, but these data were not available for 
analysis. None of the studies addressed CrAg screening and pre-emptive therapy in ART-
experienced patients though growing evidence suggests a considerable proportion of patients 
with advance HIV due to failing ART. 
Authors’ conclusion  
Offering fluconazole pre-emptive therapy at presently recommended doses to CrAg-positive 
patients compared to no fluconazole, substantially reduces the risk of incident CM and may 
have survival benefits. The high prevalence of asymptomatic CM in CrAg-positive patients 
together with low uptake of lumbar puncture, justifies the development of reliable point-of-
care tests capable at point of screening, of identifying CrAg-positive patients at higher risk of 
underlying asymptomatic CM. The availability of sustainable fluconazole in ART programs 
is essential for effective pre-emptive strategies.  
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TABLES AND LEGEND OF FIGURES 
Table 1. Characteristics of included studies and outcomes assessed per study 
Author, Year Study design 
(screening) 
CrAg 
test 
Median 
follow-up 
Country N* Fluconazole pre-emptive 
therapy 
Outcomes assessed 
       CrAg 
positivity 
Asymptomatic 
CM in CrAg+ 
CM during 
follow-up 
Mortality 
during 
follow-up 
Desmet et al (1989) 
[31] 
Prospective  LA None Democratic 
Republic of 
Congo 
450 No Yes  Yes No  No 
Liechty et al (2007) 
[32] 
Retrospective  LA > 3 months Uganda 377 No Yes No Yes Yes 
Jarvis et al (2009) 
[14]  
Retrospective  LA 1 year South Africa 707  
 
No Yes  No Yes Yes 
Meya et al (2010) 
[23] 
Prospective LA 47 months Uganda 295  
 
200 - 400 mg/day for 2 - 4 
weeks 
Yes  No Yes Yes 
Pongsai et al (2010) 
[33]  
Retrospective LA 1 year Thailand 85  
 
Yes (dose not reported) Yes  Yes Yes No 
Mamoojee et al 
(2011) [34] 
Retrospective  LA Not 
reported 
Ghana 92  
 
No Yes No No No 
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Linares et al (2012) 
[35] 
Retrospective  LFA 1 year Peru 365  
 
No Yes No Yes Yes 
Osazuwa et al 
(2012) [36] 
Cross-
sectional 
LA None Nigeria 81  
 
No Yes No No No 
Smith et al (2013) 
[26] 
Retrospective LFA None Vietnam 226  
 
No Yes No No No 
Ganiem et al 
(2014) [37] 
Retrospective  LFA HIV 
diagnosis till 
incidence of 
death  
Indonesia 810 
 
No 
(primary prophylaxis: < 
200 CD4) 
Yes No No No  
Mckenney et al 
(2014) [38] 
Retrospective LFA Not reported USA 1,872 Not reported Yes No No No 
Manabe et al 
(2015) [39] 
Prospective LA > 1 year USA 117  
 
Yes (at physician’s 
discretion) 
Yes No Yes Yes 
Pac et al (2015) 
[41] 
Prospective LA 6 months Uganda 177  
 
800 mg/day for four weeks Yes Yes Yes Yes 
Kapoor et al (2015) 
[22] 
Prospective 
 
LFA 6 months Tanzania 216  
 
800 mg/day for two weeks, 
then 400mg/day for two 
weeks 
Yes No Yes Yes 
Mfinanga et al Prospective LFA 1 year Tanzania and 
Zambia 
717  
 
**WHO recommended 
dose 
Yes Yes No Yes 
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(2015) [40] 
Chipungu et al 
(2015) [42] 
Prospective LFA 6 months Malawi 113  
 
**WHO recommended 
dose 
Yes No Yes No 
Vallabhaneni et al 
(2015) [44] 
Retrospective 
 
LA 1 year South Africa 1,170 
 
Yes (at physician’s 
discretion) 
Yes No Yes No 
Ezeanolue et al 
(2016) [46] 
Retrospective LFA Not reported Nigeria 2,752 
 
No Yes No No No 
Longley et al 
(2016) [45] 
Prospective 
 
LFA 1 year South Africa 645  
 
**WHO recommended 
dose 
Yes Yes Yes Yes 
Morawski et al 
(2016) [43] 
Prospective LFA 1 year Uganda 2,135  
 
**WHO recommended 
dose 
Yes No Yes Yes 
Ogouyemi-Hounto 
et al (2016) [47] 
Cross-
sectional 
LFA None Benin 155 No  Yes No  No   No  
Frola et al (2017) 
[48] 
Prospective LFA 9 months  Argentina  123 **WHO recommended 
dose 
Yes  Yes  Yes  No  
Hajiabdolbaghi et 
al (2017) [49] 
Prospective LFA 6 months  Iran  86 No  Yes  No  Yes  No  
Kadam et al (2017) 
[50] 
Prospective LA 6 months  India  208 No  Yes  Yes  No  Yes  
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Makadzange et al 
(2017) [51] 
Cross-
sectional  
LFA 1 year  Zimbabwe  1336 **WHO recommended 
dose 
Yes  Yes  No  Yes  
Rick et al (2017) 
[52] 
Prospective LFA 5 months  Lesotho  128 **WHO recommended 
dose 
Yes  No  No  No  
Vu et al (2017) [53] Prospective  LFA 6 months  Vietnam  944 **WHO recommended 
dose 
Yes  No  No  Yes  
Nalintya et al 
(2017) [54] 
Prospective LFA 6 months  Uganda  1,440 **WHO recommended 
dose 
Yes  No  No  No  
Temfack et al 
(2018) [55] 
Prospective  LFA 1 year  Cameroon 186 **WHO recommended 
dose 
Yes  Yes  Yes  Yes  
Thomsen et al 
(2018) [56] 
Retrospective LFA  1 year  Guinea Bissau 200 No  Yes  No  No  Yes  
Wake et al (2018) 
[57] 
Cross-
sectional  
LFA None  South Africa  19,233 **WHO recommended 
dose 
Yes  Yes  No  No  
Abbreviations: CrAg, cryptococcal antigen; LA, latex agglutination; LFA, lateral flow assay; CM, cryptococcal meningitis 
*N is number of patients except for Mckenney and Ezeanolue (number of stored samples). 
**WHO recommended dose: 800 mg/day for two weeks, then 400 mg/day for 8 weeks followed by 200 mg/day till CD4 above 200 cells/μL 
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Incidence of CM during follow-up,  
% (95%CI) 
Risk ratio  
(95% CI) 
p-value 
 Interventions offered to CrAg-positive participants Number of studies N CrAg-positives CrAg-negatives   
No pre-emptive fluconazole 4 1,143 21.4 (11.6 – 34.4) 0.4 (0.1 – 0.9) 52.7 (6.4 – 431.2) 0.0002 
Any pre-emptive fluconazole 11 5,006 6.3 (3.6 – 9.9) 0.3 (0.2 – 0.5)  15.6 (4.5 – 53.8) <0.0001 
Stratified analysis  
 Pre-emptive fluconazole initiated at < 800 mg/day 4 1,635 9.1 (2.5 – 21.7) 0.6 (0.3 – 1.0) 15.9 (3.3 – 75.7) 0.0005 
 Pre-emptive fluconazole initiated at 800 mg/day 7 3,371 5.7 (3.0 – 9.7) 0.1 (0 – 0.3)  14.9 (1.9 – 111.7) 0.009 
 
Pre-emptive fluconazole initiated at 800 mg/day following 
post-screening lumbar puncture 
4 1108 0 (0 – 0.8)  0.3 (0 – 0.8)  5.7 (0.7 – 49.8)  0.12 
Abbreviations: CrAg, cryptococcal antigen; 95%CI, 95% confidence interval; N, number of participants; CM, cryptococcal meningitis. 
  
Table 2. Incidence of cryptococcal meningitis during follow-up 
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Table 3. All-cause mortality rates during follow-up 
  
  
All-cause mortality during follow-up, 
% (95%CI) 
Risk ratio 
(95% CI) 
p-value 
 Interventions offered to CrAg-positive participants Number of studies N CrAg-positives CrAg-negatives   
No pre-emptive fluconazole 4 1099 39.7 (28.8 – 51.5) 13.9 (11.8 – 16.2) 2.6 (1.8 – 3.6) <0.00001 
Any pre-emptive fluconazole 10 6605 17.9 (14.4 – 21.8) 14.1 (13.2 – 15.0) 1.7 (1.0 – 3.0) 0.06 
Stratified analysis  
 Pre-emptive fluconazole initiated at <800 mg/day 2 395 25.9 (11.1 – 46.3) 6.5 (4.2 – 9.5) 9.4 (0.04 – 2069) 0.42 
 Pre-emptive fluconazole initiated at 800 mg/day 8 6,210 17.4 (13.9 – 21.4) 14.6 (13.7 – 15.5) 1.6 (0.9 – 2.7) 0.11 
 
Pre-emptive fluconazole initiated at 800 mg/day 
following post screening lumbar puncture 
5 3060 21.3 (16.1 – 27.3) 10.7 (9.6 – 11.9) 2.2 (1.7 – 2.9) <0.00001 
Abbreviations: CrAg, cryptococcal antigen; 95%CI, 95% confidence interval; N, number of participants; CM, cryptococcal meningitis. 
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Legend of figures. 
Legends of figures:  
Figure 1. Flow diagram of the study selection process. Abbreviations: N, number of studies; CrAg, 
cryptococcal antigen; CM, cryptococcal meningitis 
Figure 2. Prevalence of CrAg positivity in patients with less than 100 CD4 cells/μL. Abbreviations: ES, effect 
size; CI, confidence interval 
Figure 3. Prevalence of asymptomatic cryptococcal meningitis among CrAg-positive patients with less than 
100 CD4 cells/μL. Abbreviations: ES, effect size; CI, confidence interval 
Figure 4. Forest plots of incidence of cryptococcal meningitis during follow-up. Abbreviations: M-H, Mantel-
Haenszel; CI, confidence interval, LP, lumbar puncture 
Figure 5. Forest plots of incidence of all-cause mortality during follow-up. Abbreviations: M-H, Mantel-
Haenszel; CI, confidence interval, LP, lumbar puncture 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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